Index by Author

September/October 2016; Volume 70,Issue 5

B

  1. Bakhshayeshi, Meisam

    1. Session 4.1: Case Studies of Application of Generic Claims and QbD for Viral Clearance
      Rachel Specht and Meisam Bakhshayeshi
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 462-469; DOI: https://doi.org/10.5731/pdajpst.2016.006957
    2. Session 4.2: Viral Spiking, Viral Preparation, and Upstream Risk Mitigation Strategies
      Meisam Bakhshayeshi and Rachel Specht
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 470-476; DOI: https://doi.org/10.5731/pdajpst.2016.006965

  2. Blümel, Johannes

    1. Session 5: Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments
      Glen Bolton and Johannes Blümel
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 477-481; DOI: https://doi.org/10.5731/pdajpst.2016.006973
    2. Session 2: Company-Specific Data on Cycled Resin Testing
      Johannes Blümel and Kurt Brorson
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 428-442; DOI: https://doi.org/10.5731/pdajpst.2016.006924

  3. Bolton, Glen

    1. Session 5: Conference Summary: Key Discussion and Outcomes, Pending Questions, and Proposed Experiments
      Glen Bolton and Johannes Blümel
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 477-481; DOI: https://doi.org/10.5731/pdajpst.2016.006973
    2. Introduction: Proceedings of the 2015 Viral Clearance Symposium
      Glen Bolton and Rich Levy
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 409; DOI: https://doi.org/10.5731/pdajpst.2016.006874

  4. Brorson, Kurt

    1. Session 2: Company-Specific Data on Cycled Resin Testing
      Johannes Blümel and Kurt Brorson
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 428-442; DOI: https://doi.org/10.5731/pdajpst.2016.006924

  5. Buhlmann, Bob

    1. PDA Points To Consider: Fundamental Concepts in Data Integrity
      Bob Buhlmann, Madlene Dole and Zena Kaufmann
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 482-488; DOI: https://doi.org/10.5731/pdajpst.2016.007062

C

  1. Chen, Dayue

    1. Session 3.1: Protein A, Hydroxyapatite, and Mixed-Mode Chromatography
      Dayue Chen
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 443-450; DOI: https://doi.org/10.5731/pdajpst.2016.006932

D

  1. Dole, Madlene

    1. PDA Points To Consider: Fundamental Concepts in Data Integrity
      Bob Buhlmann, Madlene Dole and Zena Kaufmann
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 482-488; DOI: https://doi.org/10.5731/pdajpst.2016.007062

G

  1. Gallo, Christopher

    1. Session 3.2: Viral Clearance of Emerging Unit Operations: Membrane Chromatography, Other Methods, Etc.
      Christopher Gallo
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 451-461; DOI: https://doi.org/10.5731/pdajpst.2016.006940

K

  1. Kaufmann, Zena

    1. PDA Points To Consider: Fundamental Concepts in Data Integrity
      Bob Buhlmann, Madlene Dole and Zena Kaufmann
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 482-488; DOI: https://doi.org/10.5731/pdajpst.2016.007062

L

  1. Levy, Rich

    1. Introduction: Proceedings of the 2015 Viral Clearance Symposium
      Glen Bolton and Rich Levy
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 409; DOI: https://doi.org/10.5731/pdajpst.2016.006874

M

  1. Ma, Junfen

    1. Session 1.1: Viral Clearance Using Traditional, Well-Understood Unit Operations: Low pH and Detergent Viral Inactivation
      Junfen Ma and David Roush
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 410-416; DOI: https://doi.org/10.5731/pdajpst.2016.006890
    2. Viral Clearance Using Traditional, Well-Understood Unit Operations Session 1.2: Virus-Retentive Filtration
      David Roush and Junfen Ma
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 417-427; DOI: https://doi.org/10.5731/pdajpst.2016.006916

R

  1. Roush, David

    1. Session 1.1: Viral Clearance Using Traditional, Well-Understood Unit Operations: Low pH and Detergent Viral Inactivation
      Junfen Ma and David Roush
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 410-416; DOI: https://doi.org/10.5731/pdajpst.2016.006890
    2. Viral Clearance Using Traditional, Well-Understood Unit Operations Session 1.2: Virus-Retentive Filtration
      David Roush and Junfen Ma
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 417-427; DOI: https://doi.org/10.5731/pdajpst.2016.006916

S

  1. Specht, Rachel

    1. Session 4.1: Case Studies of Application of Generic Claims and QbD for Viral Clearance
      Rachel Specht and Meisam Bakhshayeshi
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 462-469; DOI: https://doi.org/10.5731/pdajpst.2016.006957
    2. Session 4.2: Viral Spiking, Viral Preparation, and Upstream Risk Mitigation Strategies
      Meisam Bakhshayeshi and Rachel Specht
      PDA Journal of Pharmaceutical Science and Technology September 2016, 70 (5) 470-476; DOI: https://doi.org/10.5731/pdajpst.2016.006965
Back to top

In This Issue